Stay updated on IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial page.

Latest updates to the IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial page
- Check5 days agoChange DetectedRemoved disease-related topic tags 'Ovarian cancer' and related 'MedlinePlus Genetics' from the page. Core study information and trial details remain unchanged.SummaryDifference0.2%

- Check12 days agoChange DetectedThe study status is listed as Completed with Actual start date 2019-10-17 and completion date 2022-10-03. Revision v3.3.3 is noted and related topics like Ovarian cancer and MedlinePlus Genetics are added.SummaryDifference3%

- Check20 days agoChange DetectedRemoved 'Ovarian cancer' and 'MedlinePlus Genetics' from the related topics/MeSH terms section; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedAdded related topic links: Ovarian cancer and MedlinePlus Genetics, expanding the related topics section on the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check41 days agoChange DetectedMinor wording updates were made to the PubMed publications note to clarify auto-fill behavior, and the revision indicator was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedFooter changes removed the government funding status notice and the 'Ovarian cancer - related topics' link. These removals do not affect the study details, enrollment criteria, or outcomes.SummaryDifference0.6%

Stay in the know with updates to IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial page.